

Draft used for interview 1/7/03
S/N 09/503,559

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Roland Valdes, Jr. et al.

Examiner: Ulrike Winkler

Serial No.: 09/503,559

Group Art Unit: 1648

Filed: February 11, 2000

Docket: 1160.003US1

Title: DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC & THERAPEUTIC
COMPOSITIONS AND METHODSAMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111Commissioner for Patents
Washington, D.C. 20231

Applicant has reviewed the Office Action mailed on October 1, 2002. Please amend the above-identified patent application as follows.

This response is accompanied by a Petition, as well as the appropriate fee, to obtain a one-month extension of the period for responding to the Office action, thereby moving the deadline for response from January 1, 2003 to February 1, 2003.

IN THE CLAIMS

Please substitute the claim set in the appendix entitled Clean Version of Pending Claims for the previously pending claim set. The substitute claim set is intended to reflect cancellation of claim 4, and amendment of previously pending claims 1-3.

Please cancel claim 4. Please amend claim 1 as follows:

1. [Amended] A purified mammalian dihydroouabain-like factor (Dh-OLF) having binding reactivity with antibody raised against plant-related dihydroouabain (dho), and having 10-fold lower potency than ouabain-like factor (OLF) for inhibiting sodium pump activity and 3-fold higher potency than dho for inhibiting sodium pump activity.

2. [Amended] The factor of claim 1 having the same [a] high pressure liquid chromatography elution pattern as dho-B [similar to dho].